These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37267108)

  • 1. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
    Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
    Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Roles of Glutamine Metabolism in Benign and Malignant Cartilage Tumors With IDH Mutations.
    Zhang H; Puviindran V; Nadesan P; Ding X; Shen L; Tang YJ; Tsushima H; Yahara Y; Ban GI; Zhang GF; Karner CM; Alman BA
    J Bone Miner Res; 2022 May; 37(5):983-996. PubMed ID: 35220602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
    Amary MF; Bacsi K; Maggiani F; Damato S; Halai D; Berisha F; Pollock R; O'Donnell P; Grigoriadis A; Diss T; Eskandarpour M; Presneau N; Hogendoorn PC; Futreal A; Tirabosco R; Flanagan AM
    J Pathol; 2011 Jul; 224(3):334-43. PubMed ID: 21598255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 Mutation Induces HIF-1
    Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
    Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
    Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
    Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Profiling Identifies Association of
    Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
    Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.
    Denu RA; Yang RK; Lazar AJ; Patel SS; Lewis VO; Roszik J; Livingston JA; Wang WL; Shaw KR; Ratan R; Zarzour MA; Bird J; Raza S; Akdemir KC; Rodon Ahnert J; Subbiah V; Patel S; Conley AP
    Clin Cancer Res; 2023 Dec; 29(23):4844-4852. PubMed ID: 37747813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract.
    Tallegas M; Miquelestorena-Standley É; Labit-Bouvier C; Badoual C; Francois A; Gomez-Brouchet A; Aubert S; Collin C; Tallet A; de Pinieux G
    Hum Pathol; 2019 Feb; 84():183-191. PubMed ID: 30296521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular cholesterol biosynthesis in enchondroma and chondrosarcoma.
    Zhang H; Wei Q; Tsushima H; Puviindran V; Tang YJ; Pathmanapan S; Poon R; Ramu E; Al-Jazrawe M; Wunder J; Alman BA
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31039139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of IDH mutations in chondrosarcoma.
    Nakagawa M; Sekimizu M; Endo M; Kobayashi E; Iwata S; Fukushima S; Yoshida A; Kitabayashi I; Ichikawa H; Kawai A; Nakatani F
    J Orthop Sci; 2022 Nov; 27(6):1315-1322. PubMed ID: 34531086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
    Nakagawa M; Nakatani F; Matsunaga H; Seki T; Endo M; Ogawara Y; Machida Y; Katsumoto T; Yamagata K; Hattori A; Fujita S; Aikawa Y; Ishikawa T; Soga T; Kawai A; Chuman H; Yokoyama N; Fukushima S; Yahiro K; Kimura A; Shimada E; Hirose T; Fujiwara T; Setsu N; Matsumoto Y; Iwamoto Y; Nakashima Y; Kitabayashi I
    Oncogene; 2019 Oct; 38(42):6835-6849. PubMed ID: 31406254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas.
    Damato S; Alorjani M; Bonar F; McCarthy SW; Cannon SR; O'Donnell P; Tirabosco R; Amary MF; Flanagan AM
    Histopathology; 2012 Jan; 60(2):363-5. PubMed ID: 22074484
    [No Abstract]   [Full Text] [Related]  

  • 14. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
    Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
    Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
    Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
    Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
    Arai M; Nobusawa S; Ikota H; Takemura S; Nakazato Y
    Brain Tumor Pathol; 2012 Oct; 29(4):201-6. PubMed ID: 22323113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct IDH1/2-associated Methylation Profile and Enrichment of
    Dermawan JKT; Nafa K; Mohanty A; Xu Y; Rijo I; Casanova J; Villafania L; Benhamida J; Kelly CM; Tap WD; Boland PJ; Fabbri N; Healey JH; Ladanyi M; Lu C; Hameed M
    Cancer Res Commun; 2023 Mar; 3(3):431-443. PubMed ID: 36926116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant IDH is sufficient to initiate enchondromatosis in mice.
    Hirata M; Sasaki M; Cairns RA; Inoue S; Puviindran V; Li WY; Snow BE; Jones LD; Wei Q; Sato S; Tang YJ; Nadesan P; Rockel J; Whetstone H; Poon R; Weng A; Gross S; Straley K; Gliser C; Xu Y; Wunder J; Mak TW; Alman BA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2829-34. PubMed ID: 25730874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes.
    Pathmanapan S; Ilkayeva O; Martin JT; Loe AKH; Zhang H; Zhang GF; Newgard CB; Wunder JS; Alman BA
    Cancer Metab; 2021 Mar; 9(1):13. PubMed ID: 33762012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
    Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
    Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.